HOME
/
NEWS
/
CLINICAL TRIALS
/
ROCHE ANNOUNCES START OF SECOND PART OF PHASE 2 CLINICAL TRIALS FOR SUNFISH

News

The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

Roche announces start of second part of Phase 2 clinical trials for SUNFISH
We are pleased to share with you that Roche has announced that the dose selection for part 2 of the SUNFISH trial has been confirmed. This marks the start of part 2 of Phase 2 in SUNFISH.
Sunfish examines RG7916 in people aged 2 – 25 years with Type 2/3 SMA.
Resources
About RG7916
Community Update by Roche – September 2017